Rinri Therapeutics

CompanyUnited KingdomROR

Rinri Therapeutics develops one asset, in phase 1 (Rincell-1 in auditory neuropathy). Mostly cell therapy acting on stem cell maintenance; based in the United Kingdom.

Assets
1
Furthest
Phase 1
Trials
1
Signals
0

Pipeline

1

  • Rincell-1

    Otic neural progenitor cell therapy to replace damaged auditory neurons and restore hearing function

    Phase 1Cell therapyStem cell maintenanceauditory neuropathypresbyacusis

Full company profiles: pipeline, trials, funding and people.

See Pro
  • Evidence behind the mechanisms1
  • Trials1
  • Similar companies6

Updated 7 Oct 2026 · 2 sources

Intelligence